La cadena de opciones muestra datos clave de las opciones de acciones de Sagimet Biosciences a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Sagimet Biosciences..

Sagimet Biosciences (NASDAQ:SGMT) Bolsa, Cadena de Opciones

SAGIMET BIOSCIENCES INC-A

Sagimet Biosciences

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences Inc

Macro Economic Events

WIIM

Economics

Oil is trading higher amid concerns of Israel-Iran escalation. President Trump denied working on a ceasefire and said everyone should evacuate Tehran.

<p><strong>Improved margin, accelerated sales cycle and complete end-user proposition delivered through joint offering</strong></p>
<p>Arctera, a global leader in data management, Wasabi Technologies, the hot cloud storage company, and TD SYNNEX, a leading global distributor and solutions aggregator for the IT ecosystem, today announced a joint channel-ready data protection solution to simplify sales for channel resellers. The new offering combines Arctera Backup Exec with Wasabi Hot Cloud Storage into a single offering available to channel partners through TD SYNNEX.</p>
<p>The joint solution is available today through TD SYNNEX in North America. The organizations intend to expand availability internationally later this year.</p>


News

Arctera, Wasabi Technologies, And TD SYNNEX Announce Joint Channel-Ready Data Protection Solution To Simplify Sales For Channel Resellers

<p>Argus Research  analyst Christine Dooley   maintains Tapestry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) with a Buy and raises the price target from $78 to $92.</p>


Price Target

Analyst Ratings

Argus Research Maintains Buy on Tapestry, Raises Price Target to $92

<p>Morgan Stanley  analyst Josh Baer   initiates coverage on Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) with a Equal-Weight rating and announces Price Target of $330.</p>


Initiation

MNDY

Morgan Stanley Initiates Coverage On Monday.Com with Equal-Weight Rating, Announces Price Target of $330

<p>Lake Street  analyst Eric Martinuzzi   maintains TechTarget (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTGT#NASDAQ">TTGT</a>) with a Buy and lowers the price target from $12 to $10.</p>


TTGT

Lake Street Maintains Buy on TechTarget, Lowers Price Target to $10

<p><strong>CERo Therapeutics Holdings Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares are trading higher Tuesday after the company received&nbsp;U.S. Food and Drug Administration (FDA) <a href="https://www.benzinga.com/pressreleases/25/06/g45970518/cero-therapeutics-holdings-inc-announces-fda-orphan-drug-designation-granted-to-cer-1236-for-the-t">Orphan Drug Designation for CER-1236</a>.</p>
<p><strong>What Happened:</strong> Immunotherapy company Cero Therapeutics announced that the FDA granted Orphan Drug Designation for its lead drug candidate CER-1236 for the treatment of acute myeloid leukemia.</p>
<p>CER-1236 is a therapy that engineers a cancer patient&#8217;s own T cell therapeutics that deploy target-cell eating mechanisms alongside the range of natural target cell destroying mechanisms used by T cells. The therapy is currently in Phase1 clinical trials for acute myeloid leukemia. </p>
<p>&#8220;Orphan Drug Designation underscores the importance of developing new treatments for AML, and the potential for CER-1236 to provide a new and differentiated approach toward treatment,&#8221; said <strong>Chris Ehrlich</strong>, CEO of Cero Therapeutics.</p>
<p>&#8220;We believe that we are at the forefront of innovation in immuno-oncology and are grateful for the recognition from FDA.&nbsp; We look forward to providing updates on our trial in the near term.&#8221;</p>
<p>Cero Therapeutics noted that the Orphan Drug Designation opens the door for potential incentives, including FDA assistance in designing clinical trials, access to grants, exemption from drug approval application fees and eligibility for seven years of marketing exclusivity.</p>
<p>Cero Therapeutics had a market cap of just $2.83 million as of Monday&#8217;s close, with a total float of around 384,000 shares, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. Low-float micro-cap stocks tend to be extremely volatile.</p>
<h3 class="wp-block-heading">How To Buy CERO Stock</h3>
<p>By now you're likely curious about how to participate in the market for Cero Therapeutics &#8211; be it to purchase shares, or even attempt to bet against the company.</p>
<p>Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.</p>
<p>If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a>  Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.</p>
<p><strong>CERO Price Action:</strong> <a href="http://benzinga.com/quote/CERO">Cero Therapeutics shares</a> were up 118.8% at $14.95 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.</p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/m-a/25/06/45970361/eli-lilly-expands-into-gene-editing-with-verve-therapeutics-acquisition"><strong>Eli Lilly Expands Into Gene Editing With Verve Therapeutics Acquisition</strong></a></li>
</ul>
<p><em>Photo: Shutterstock.</em></p>


Movers

CERO

What's Going On With Cero Therapeutics Stock Tuesday?

<p>Argus Research  analyst Stephen Biggar   maintains BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) with a Buy and raises the price target from $1028 to $1090.</p>


Argus Research Maintains Buy on BlackRock, Raises Price Target to $1090

<p>Craig-Hallum  analyst Anthony Stoss   maintains Digital Turbine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPS#NASDAQ">APPS</a>) with a Buy and raises the price target from $4 to $7.</p>


APPS

Craig-Hallum Maintains Buy on Digital Turbine, Raises Price Target to $7

<p>Deep-pocketed investors have adopted a bullish approach towards Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CVNA usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 13 extraordinary options activities for Carvana. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 76% leaning bullish and 15% bearish. Among these notable options, 5 are puts, totaling $204,103, and 8 are calls, amounting to $401,947.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $200.0 to $335.0 for Carvana over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Carvana's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Carvana's whale activity within a strike price range from $200.0 to $335.0 in the last 30 days. </p>
<h3>Carvana 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750168939_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CVNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$22.25</td>
<td>$21.15</td>
<td>$22.3</td>
<td>$320.00</td>
<td>$111.5K</td>
<td>625</td>
<td align="right">52</td>
</tr>
<tr>
<td>CVNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$44.5</td>
<td>$42.7</td>
<td>$42.7</td>
<td>$335.00</td>
<td>$72.5K</td>
<td>1.6K</td>
<td align="right">17</td>
</tr>
<tr>
<td>CVNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$145.1</td>
<td>$145.1</td>
<td>$145.1</td>
<td>$200.00</td>
<td>$72.5K</td>
<td>100</td>
<td align="right">5</td>
</tr>
<tr>
<td>CVNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/11/25</td>
<td>$21.55</td>
<td>$19.95</td>
<td>$21.55</td>
<td>$285.00</td>
<td>$62.4K</td>
<td>36</td>
<td align="right">31</td>
</tr>
<tr>
<td>CVNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/27/25</td>
<td>$8.9</td>
<td>$8.2</td>
<td>$8.72</td>
<td>$300.00</td>
<td>$43.6K</td>
<td>127</td>
<td align="right">53</td>
</tr>
</tbody>
</table>
</p>
<h3>About Carvana</h3>
<p>Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage. The foundation of the business is retail vehicle unit sales. This drives the majority of the revenue and allows the company to capture additional revenue streams associated with financing, VSCs, auto insurance and GAP waiver coverage, as well as trade-in vehicles.</p>
<p>Following our analysis of the options activities associated with Carvana, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Carvana</h3>
<ul>
<li>Trading volume stands at 406,154, with CVNA's price up by 1.38%, positioned at $294.06.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 43 days.</li>
</ul>
<h3>What The Experts Say On Carvana</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $357.5.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Buy rating for Carvana, targeting a price of $375.<br />
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Carvana, targeting a price of $340. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Carvana options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Options

Markets

CVNA

Carvana Unusual Options Activity For June 17

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Palantir Technologies</strong>.</p>
<p>Looking at options history for Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) we detected 23 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 30% of the investors opened trades with bullish expectations and 56% with bearish.</p>
<p>From the overall spotted trades, 9 are puts, for a total amount of $301,001 and 14, calls, for a total amount of $768,738.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $110.0 to $167.5 for Palantir Technologies during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In today's trading context, the average open interest for options of Palantir Technologies stands at 4351.2, with a total volume reaching 27,357.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Palantir Technologies, situated within the strike price corridor from $110.0 to $167.5, throughout the last 30 days.</p>
<h3>Palantir Technologies Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750168934_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$2.45</td>
<td>$2.4</td>
<td>$2.4</td>
<td>$141.00</td>
<td>$120.4K</td>
<td>2.8K</td>
<td>1.6K</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/03/25</td>
<td>$4.9</td>
<td>$4.8</td>
<td>$4.81</td>
<td>$145.00</td>
<td>$117.6K</td>
<td>1.8K</td>
<td>632</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$8.1</td>
<td>$6.9</td>
<td>$7.65</td>
<td>$145.00</td>
<td>$76.5K</td>
<td>5.8K</td>
<td>1</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$27.5</td>
<td>$26.95</td>
<td>$27.23</td>
<td>$125.00</td>
<td>$57.1K</td>
<td>3.1K</td>
<td>27</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/03/25</td>
<td>$5.55</td>
<td>$5.4</td>
<td>$5.44</td>
<td>$143.00</td>
<td>$54.4K</td>
<td>1.7K</td>
<td>277</td>
</tr>
</tbody>
</table>
</p>
<h3>About Palantir Technologies</h3>
<p>Palantir is an analytical software company that focuses on leveraging data to create efficiencies in its clients' organizations. The firm serves commercial and government clients via its Foundry and Gotham platforms, respectively. Palantir works only with entities in Western-allied nations and reserves the right not to work with anyone that is antithetical to Western values. The Denver-based company was founded in 2003 and went public in 2020.</p>
<h3>Current Position of Palantir Technologies</h3>
<ul>
<li>Currently trading with a volume of 10,374,598, the PLTR's price is down by -1.22%, now at $139.68. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 48 days.</li>
</ul>
<h3>Professional Analyst Ratings for Palantir Technologies</h3>
<p>A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $135.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Mizuho keeps a Underperform rating on Palantir Technologies with a target price of $116.<br />
&#x2A; Consistent in their evaluation, an analyst from Loop Capital keeps a Buy rating on Palantir Technologies with a target price of $155. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Palantir Technologies, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


PLTR

Looking At Palantir Technologies's Recent Unusual Options Activity

Walmart And Soda Health Collaborate To Launch Walmart Everyday Health Signals Program To Select Medicare Advantage And Medicaid Members

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>MARA Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MARA, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 8 uncommon options trades for MARA Holdings.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 62% bullish and 25%, bearish.</p>
<p>Out of all of the special options we uncovered, 3 are puts, for a total amount of $81,840, and 5 are calls, for a total amount of $150,275.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $11.0 to $30.0 for MARA Holdings during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for MARA Holdings's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across MARA Holdings's significant trades, within a strike price range of $11.0 to $30.0, over the past month.</p>
<h3>MARA Holdings Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750168929_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MARA</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$3.4</td>
<td>$3.15</td>
<td>$3.28</td>
<td>$16.00</td>
<td>$32.8K</td>
<td>784</td>
<td>0</td>
</tr>
<tr>
<td>MARA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$4.05</td>
<td>$4.0</td>
<td>$4.05</td>
<td>$11.00</td>
<td>$32.4K</td>
<td>140</td>
<td>80</td>
</tr>
<tr>
<td>MARA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/27/25</td>
<td>$0.85</td>
<td>$0.84</td>
<td>$0.84</td>
<td>$15.00</td>
<td>$29.4K</td>
<td>2.8K</td>
<td>592</td>
</tr>
<tr>
<td>MARA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/03/25</td>
<td>$0.82</td>
<td>$0.76</td>
<td>$0.83</td>
<td>$15.00</td>
<td>$29.0K</td>
<td>651</td>
<td>1.0K</td>
</tr>
<tr>
<td>MARA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$0.97</td>
<td>$0.96</td>
<td>$0.96</td>
<td>$30.00</td>
<td>$28.8K</td>
<td>17.9K</td>
<td>300</td>
</tr>
</tbody>
</table>
</p>
<h3>About MARA Holdings</h3>
<p>MARA Holdings Inc leverages digital asset compute to support the energy transformation. It secures the blockchain ledger and supports the energy transformation by converting clean, stranded, or underutilized energy into economic value. The company also offers technology solutions to optimize data center operations, including next-generation liquid immersion cooling and firmware for bitcoin miners. It is focused on computing for, acquiring, and holding digital assets as a long-term investment.</p>
<p>Having examined the options trading patterns of MARA Holdings, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of MARA Holdings</h3>
<ul>
<li>With a volume of 4,339,969, the price of MARA is down -3.46% at $14.79. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 44 days.</li>
</ul>
<h3>What The Experts Say On MARA Holdings</h3>
<p>A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $19.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from JP Morgan persists with their Neutral rating on MARA Holdings, maintaining a target price of $19.<br />
&#x2A; An analyst from Rosenblatt persists with their Buy rating on MARA Holdings, maintaining a target price of $20. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for MARA Holdings, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


MARA

Decoding MARA Holdings's Options Activity: What's the Big Picture?

<p><a href="https://www.bloomberg.com/news/articles/2025-06-17/rfk-jr-plans-crackdown-on-pharma-ads-in-threat-to-10-billion-market" title="https://www.bloomberg.com/news/articles/2025-06-17/rfk-jr-plans-crackdown-on-pharma-ads-in-threat-to-10-billion-market">https://www.bloomberg.com/news/articles/2025-06-17/rfk-jr-plans-crackdown-on-pharma-ads-in-threat-to-10-billion-market</a></p>


Biotech

General

'RFK Jr. Plans Crackdown on Pharma Ads in Threat to $10 Billion Market' - Bloomberg News

<p>Craig-Hallum  analyst Albert Lowe   initiates coverage on Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) with a Buy rating and announces Price Target of $50.</p>


NGNE

Craig-Hallum Initiates Coverage On Neurogene with Buy Rating, Announces Price Target of $50

<p>Waymo's self-driving taxis may not yet deliver the low-cost promise often associated with autonomous vehicles, but that isn't stopping riders from paying a premium — or worrying about safety.</p>
<p>A new pricing study by ride data platform Obi, found 74% of riders cite safety as their top concern around robotaxis — even as they continue to choose Waymo's higher-priced service. In San Francisco, Waymo rides averaged $20.43, compared to $15.58 for UberX and $14.44 for Lyft Standard — a 31% to 41% markup over traditional ride-hailing options.</p>
<p><strong>Don't Miss:</strong></p>
<ul class="wp-block-list">
<li><strong>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing"><strong>this is your last chance to become an investor for $0.80 per share.</strong></a></strong></li>
<li><strong>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor"><strong>with $1,000 you can invest at just $0.30/share!</strong></a></strong></li>
</ul>
<p>The data, drawn from nearly 90,000 ride offers collected between March 25 and April 25, compared real-time quotes and ETAs for matched trips across Waymo, Uber Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>), and Lyft Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>).</p>
<p>Despite the higher fares, the survey component of the report reveals that 70% of riders who've tried Waymo prefer it over a traditional rideshare, and a surprising share are even willing to pay more for the driverless experience.</p>
<h2 class="wp-block-heading">Demand Remains Strong Despite High Prices</h2>
<p>The Obi report, titled <em>"</em>The Road Ahead: Pricing Insights On Waymo, Uber and Lyft<em>"</em>, is being described as the first in-depth analysis of Waymo's pricing strategy by <a href="https://techcrunch.com/2025/06/12/waymo-rides-cost-more-than-uber-or-lyft-and-people-are-paying-anyway/">TechCrunch</a>. Among key findings, Waymo's pricing was significantly higher not only on average, but also at specific times, especially during peak hours.</p>
<p>At evening rush hour – 5 p.m. to 6 p.m. – Waymo rides were $11 more than Lyft and $9.50 more than Uber, according to the study. For short trips under 1.4 kilometers, Waymo charged up to $26.46 per kilometer, roughly 41.5% more than Uber and 31.1% more than Lyft on comparable routes.</p>
<p>Still, riders don't seem to mind.</p>
<p>In a survey of 507 riders conducted by Obi across San Francisco, Los Angeles, and Phoenix, 70% of those who had used Waymo said they preferred driverless rides to traditional taxi or rideshare services.</p>
<p><strong>Trending: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"><strong> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</strong></a>.</strong></p>
<h2 class="wp-block-heading">But Safety Remains a Major Concern</h2>
<p>Obi's survey also found that 74% of respondents cited safety as their biggest concern around autonomous vehicles. Despite having a positive ride experience, more than two-thirds said driverless cars should still have remote human monitoring, a practice Waymo currently employs.</p>
<p>"There's something about being in the car alone," Obi's chief revenue officer, Ashwini Anburajan, told TechCrunch. "It is there for you to, like, kind of live in a little bubble and get from point A to point B, and be very comfortable doing so."</p>
<p>Safety concerns were particularly high among older adults and women, with only 34% of women saying they would trust a Waymo to transport their child, compared to 48% of men, according to Obi's findings.</p>
<h2 class="wp-block-heading">Pricing Patterns Suggest Limited Supply, Basic Algorithms</h2>
<p>Anburajan explained that Waymo's higher prices and variability may be driven by a less sophisticated pricing model than Uber or Lyft, whose platforms benefit from a decade of real-time data and driver fluctuations. With Waymo's fixed and slowly expanding fleet, pricing appears more directly influenced by supply-demand imbalances.</p>
<p>The study found a positive correlation between price and wait time, especially during high-demand periods like Friday and Saturday evenings. Longer ETA often translated directly to higher fares, with Waymo showing the highest elasticity in its afternoon time window.</p>
<p><strong><em>See Also: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning"><strong><em>Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</em></strong></a></em></strong></p>
<h2 class="wp-block-heading">Mixed Regional Anecdotes Add Nuance</h2>
<p>While Obi's data is focused primarily on San Francisco, Reddit users chimed in with region-specific insights, suggesting Waymo's pricing model might be more variable elsewhere.</p>
<p>"In Phoenix, I found Waymo to be cheaper than Uber and Lyft," wrote one user on <a href="https://www.reddit.com/r/technology/comments/1l9lmwa/waymo_rides_cost_more_than_uber_or_lyft_and/">r/technology</a>. Another noted, "In LA, about half the time Waymo was on par or cheaper — but the 15+ minute wait time occasionally pushed me back to traditional ride shares."</p>
<p>"Safety issue too. The chances of getting raped in a Waymo are much lower than in an Uber because of the lack of drivers," one more user noted.</p>
<p>These anecdotes hint that Waymo's pricing and adoption trends may vary by city.</p>
<h2 class="wp-block-heading">The Big Picture: Premium, Not Mass-Market (Yet)</h2>
<p>For now, Waymo, owned by Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>, GOOGL)), is reportedly handling over 250,000 paid rides weekly across multiple cities — and claims over 20% market share in San Francisco service zones, according to <a href="https://www.thedriverlessdigest.com/p/waymo-stats-2025-funding-growth-coverage">The Driverless Digest</a>.</p>
<p>The Obi data shows that despite fears, consumer behavior is leaning toward premium autonomous experiences, at least in urban tech hubs. Whether this translates into sustained market dominance or niche adoption remains to be seen, but the willingness to pay more for a driverless ride is here.</p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a></strong><strong> Here&#8217;s what Americans think you need to be considered wealthy.</strong></li>
<li><strong>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – Many are rushing to <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>grab 4,000 of its pre-IPO shares for just $0.30/share!</strong></a></strong></li>
</ul>
<p><em><strong>Image: Shutterstock</strong></em></p>


GOOG

LYFT

UBER

Nearly 75% of Riders Fear Robotaxi Safety – Yet Pay More for Waymo's Driverless Experience

<p><strong>Boeing Co.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) and <strong>Lockheed Martin Corp </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) are touting their defense credentials in a bid to secure more contracts in the development of President <strong>Donald Trump</strong>'s Golden Dome missile defense system.</p>
<p><strong>What Happened: </strong>"We clearly have a whole number of product lines that will contribute very well, that are going to fit very well with what is necessary to achieve the mission," said <strong>Tim Cahill</strong>, president of Missiles and Fire Control at Lockheed Martin, in a Reuters report published Monday.</p>
<p>The report outlines that Lockheed Martin already supplies key components that could be incorporated into the Golden Dome, including missile detection systems and other components.</p>
<p>Boeing, too, has signaled its involvement. Interim Defense and Space CEO <strong>Steve Parker</strong> noted that the aerospace giant has "done a lot of work" on the project, according to the report.</p>
<p><strong>Why It Matters: </strong>The news comes in as Trump's Golden Dome project is being eyed by several key players in the defense space as well as in Silicon Valley. Companies like <strong>SpaceX</strong>, <strong>Palantir Technologies Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) have <a href="https://www.benzinga.com/25/04/44861620/spacex-palantir-frontrunners-in-bid-that-could-build-donald-trumps-golden-dome-report">emerged as frontrunners</a> for key projects in the initiative.</p>
<p>The project, which will reportedly cost over $175 billion, has also faced criticism from experts, who believe it could trigger a new <a href="https://www.benzinga.com/general/space/25/05/45584539/donald-trumps-175-billion-golden-dome-could-trigger-a-new-space-arms-race-expert-warns-its-opening-a-pandoras-box">space-based weapons</a> arms race throughout the globe.</p>
<p><strong>Xi Jinping</strong>'s China has <a href="https://www.benzinga.com/markets/25/05/45541866/xi-jinpings-china-wants-trump-to-immediately-drop-the-golden-dome-project-over-strong-offensive-implications-security-of-all-countries-should-not-be-compromised">expressed serious concerns </a>about the initiative, as officials from the CCP have urged the Trump administration to reconsider its decision to go ahead with the project.</p>
<p>Boeing is grappling with serious concerns about its aircraft's safety and quality following the <a href="https://www.benzinga.com/markets/25/06/45911791/boeing-dreamliner-carrying-over-200-passengers-crashes-shortly-after-takeoff-near-indias-ahmedabad-b">fatal Air India crash</a> in Ahmedabad, which claimed over 241 lives last week. Boeing has been <a href="https://www.benzinga.com/markets/equities/25/06/45940768/boeings-troubled-2000s-from-a-sweetheart-1-1b-deal-before-deadly-air-india-crash-to-stranding-astronauts-at-iss-and-airline-crashes">embroiled in controversy</a> over its aircraft in the past few years.</p>
<p><em>Check out more of Benzinga's Future Of Mobility coverage by</em><a href="https://www.benzinga.com/topic/mobility"><em> following this link.</em></a></p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/travel/25/06/45926295/elon-musk-once-said-boeing-had-too-many-non-technical-managers-whistleblower-flagged-flawed-787-dreamliner-manufacturing-all-the-warnings-before-air-india-plane-went-down-with-242-lives">Elon Musk Once Said Boeing Had &#8216;Too Many Non-Technical Managers&#8217; — Whistleblower Flagged Flawed 787 Dreamliner Manufacturing: All the Warnings Before Air India Plane Went Down With 242 Lives Aboard</a></li>
</ul>
<p><em>Photo courtesy: JHVEPhoto / Shutterstock.com</em></p>


Equities

Boeing, Lockheed Martin Compete For Key Role In Trump's $175 Billion Golden Dome Project

<p>Euroseas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESEA#NASDAQ">ESEA</a>) is preparing to release its quarterly earnings on Wednesday, 2025-06-18. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Euroseas to report an <strong>earnings per share</strong> (EPS) of $3.70.</p>
<p>Investors in Euroseas are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Overview of Past Earnings</h3>
<p>In the previous earnings release, the company beat EPS by $0.02, leading to a 5.42% increase in the share price the following trading session.</p>
<p>Here's a look at Euroseas's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>3.31</td>
<td>3.55</td>
<td>2.82</td>
<td>2.89</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>3.33</td>
<td>3.92</td>
<td>4.92</td>
<td>2.66</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>5.0%</td>
<td>-7.000000000000001%</td>
<td>1.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750168863_0.png" alt="eps graph" /></p>
<h3>Market Performance of Euroseas's Stock</h3>
<p>Shares of Euroseas were trading at $44.52 as of June 16. Over the last 52-week period, shares are up 51.91%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/ESEA/earnings"><strong>To track all earnings releases for Euroseas visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

ESEA

Earnings Preview: Euroseas

<p>Ratings for NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) were provided by 33 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">15</td>
<td align="right">13</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">7</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for NVIDIA, revealing an average target of $166.06, a high estimate of $210.00, and a low estimate of $100.00. This current average represents a 1.52% decrease from the previous average price target of $168.62. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750168852_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The perception of NVIDIA by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tom O'Malley</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Rick Schafer</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>William Stein</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$210.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Srini Pajjuri</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$165.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Harsh Kumar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$170.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$170.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Tom O'Malley</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$170.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$135.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Matt Bryson</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$160.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$175.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Jay Goldberg</td>
<td>Seaport Global</td>
<td>Announces</td>
<td>Sell</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Blayne Curtis</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Mark Lipacis</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$200.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Srini Pajjuri</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$150.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Harsh Kumar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Matt Bryson</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$160.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$120.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$150.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Joshua Buchalter</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$140.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$125.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NVIDIA. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of NVIDIA compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for NVIDIA's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of NVIDIA's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NVDA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on NVIDIA analyst ratings.</strong></a></p>
<h2>Delving into NVIDIA's Background</h2>
<p>Nvidia is a leading developer of graphics processing units. Traditionally, GPUs were used to enhance the experience on computing platforms, most notably in gaming applications on PCs. GPU use cases have since emerged as important semiconductors used in artificial intelligence. Nvidia not only offers AI GPUs, but also a software platform, Cuda, used for AI model development and training. Nvidia is also expanding its data center networking solutions, helping to tie GPUs together to handle complex workloads.</p>
<h3>Financial Insights: NVIDIA</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Positive Revenue Trend:</strong> Examining NVIDIA's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>69.18%</strong> as of 30 April, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> NVIDIA's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>42.61%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> NVIDIA's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>23.01%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> NVIDIA's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>15.85%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> NVIDIA's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.12</strong>.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NVDA

Breaking Down NVIDIA: 33 Analysts Share Their Views

<p><strong>LiveOne</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVO#NASDAQ">LVO</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-06-18. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that LiveOne will report an <strong>earnings per share</strong> (EPS) of $-0.04. </p>
<p>LiveOne bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings Track Record</h3>
<p>In the previous earnings release, the company missed EPS by $0.05, leading to a 3.66% drop in the share price the following trading session.</p>
<p>Here's a look at LiveOne's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2025</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.01</td>
<td>-0.01</td>
<td>-0.02</td>
<td>-0.01</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.06</td>
<td>-0.02</td>
<td>-0.02</td>
<td>-0.03</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-4.0%</td>
<td>4.0%</td>
<td>0.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750168847_0.png" alt="eps graph" /></p>
<h3>Market Performance of LiveOne's Stock</h3>
<p>Shares of LiveOne were trading at $0.864 as of June 16. Over the last 52-week period, shares are down 48.78%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/LVO/earnings"><strong>To track all earnings releases for LiveOne visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Insights Ahead: LiveOne's Quarterly Earnings

<p>15 analysts have expressed a variety of opinions on Wendy's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">10</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Wendy's, revealing an average target of $14.8, a high estimate of $21.00, and a low estimate of $13.00. A 9.04% drop is evident in the current average compared to the previous average price target of $16.27. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750168832_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The perception of Wendy's by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jim Salera</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Andrew Strelzik</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$15.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Alton Stump</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$21.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Jeffrey Bernstein</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$13.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jake Bartlett</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>John Ivankoe</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>John Glass</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$13.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jim Salera</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Andrew Charles</td>
<td>TD Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$13.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jim Salera</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Dennis Geiger</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jeffrey Bernstein</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Jake Bartlett</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$17.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Chris O'Cull</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jim Salera</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Wendy's. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Wendy's compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Wendy's's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Wendy's's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/WEN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Wendy's analyst ratings.</strong></a></p>
<h2>Discovering Wendy's: A Closer Look</h2>
<p>The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $12.6 billion in 2024, narrowly edging Burger King ($11.5 billion) and clocking in well behind wide-moat McDonald's ($51.1 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spanned more than 7,200 total stores in 30 countries as of year-end 2024. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for roughly 94% of stores, and through franchise flipping and advisory fees.</p>
<h3>Financial Milestones: Wendy's's Journey</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Wendy's's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately <strong>-2.11%</strong>. This indicates a decrease in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Wendy's's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>7.49%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Wendy's's ROE excels beyond industry benchmarks, reaching <strong>20.14%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Wendy's's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.79%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>31.3</strong>, caution is advised due to increased financial risk.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Forecasting The Future: 15 Analyst Projections For Wendy's

Press Releases

Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference

Health Care

Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025

Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Sagimet Biosciences to Host Virtual KOL Event, "Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)" on May 29, 2025

Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

Sagimet Biosciences to Host Virtual KOL Event, "A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne" on June 16, 2025

Comments

Sagimet Biosciences

Sagimet Biosciences (SGMT) Opciones

Sagimet Biosciences (NASDAQ:SGMT) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL